The role of the epidermal growth factor receptor in human gliomas: II. The control of glial process extension and the expression of glial fibrillary acidic protein.
Our earlier investigations of the biology of the epidermal growth factor receptor (EGFR) in human gliomas demonstrated that the level of EGFR expression did not directly predict the glioma growth response to EGF, suggesting that the function of the EGFR in glioblastomas might not be limited to mediating the growth effects of EGF. We conducted the current studies to investigate the function(s) of the EGFR not related to growth control in human gliomas. These investigations show that the EGFR mediates the stimulative effects of EGF on glial process extension and glial fibrillary acidic protein (GFAP) expression. In addition, the level of EGFR expression correlates inversely with glioma cell responsiveness to differentiation promoting agents (for example, nerve growth factor and transforming growth factor-beta) that act through transmembrane tyrosine kinase receptors. Thus, glioma lines with a high level of EGFR expression (for example, T-98G cells) responded to fewer differentiation promoting factors than lines with a low level of EGFR expression (such as U-373MG cells). Our results suggest that the EGFR in gliomas may participate in mediating the process extension and GFAP stimulative effects of both EGF and other differentiation promoting agents. These properties represent components of the differentiated state in glia because their expression is stimulated by dibutyryl cyclic adenosine monophosphate in normal astrocytes. The involvement of the EGFR in the expression of these glial specific properties suggests that the EGFR may play an important role in glial differentiation.
Hoi Sang
U
U
Department of Surgery, University of California San Diego School of Medicine, USA.
Espiritu
O D
OD
Kelley
P Y
PY
Klauber
M R
MR
Hatton
J D
JD
D000818:Animals; D001253:Astrocytes / Q000737:chemistry / Q000502:physiology; D001932:Brain Neoplasms / Q000473:pathology*; D003994:Bucladesine / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D004797:Enzyme-Linked Immunosorbent Assay; D004815:Epidermal Growth Factor / Q000502:physiology*; D066246:ErbB Receptors / Q000032:analysis / Q000502:physiology*; D005904:Glial Fibrillary Acidic Protein / Q000032:analysis* / Q000187:drug effects; D005909:Glioblastoma / Q000473:pathology*; D006133:Growth Substances / Q000494:pharmacology; D006801:Humans; D007150:Immunohistochemistry; D009457:Neuroglia / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D005904:Glial Fibrillary Acidic Protein; D006133:Growth Substances; D014212:Tretinoin; D004815:Epidermal Growth Factor; D003994:Bucladesine; D066246:ErbB Receptors